ArticleJCO oncology practice2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
purposeFor the 10% of women diagnosed with cancer within reproductive age, reproductive health is a critical component of oncologic survivorship. Variable attention to guidelines pertaining to oncocontraception and oncofertility results in cancer care discordant with a patient's reproductive health goals, negatively affecting quality of life. This study aimed to determine if the Engendering Reproductive Health within Oncologic Survivorship (EROS) multilevel intervention improves reproductive health goal-concordant management within 3 months of cancer diagnosis. PATIENTS AND
methodsEROS is a cluster randomized trial, with 17 US-based National Cancer Institute Community Oncology Research Program (NCORP) sites (including Minority/Underserved Sites) randomly assigned to receive either reproductive health intervention (RHI; eight sites) or standard of care (SC; nine sites). Eligible patients included patients age 15-55 years with a new cancer diagnosis. The multilevel intervention included reproductive health education and navigation components. The primary study outcome is reproductive health goal-concordant management.
resultsThis ECOG-ACRIN trial enrolled 420 eligible patients from 17 NCORP sites, of which 379 had available data for the primary analysis (RHI n = 134; SC n = 245). Reproductive health goal-concordant management was achieved in 65.7% of women from RHI sites and 47.3% of women at SC sites (odds ratio [OR, RHI/SC], 2.07, 90% CI, 1.29 to 3.31). The intervention effect on reproductive health goal-concordant management was significant for women who had completed childbearing (OR [RHI/SC], 2.92 [90% CI, 1.65 to 5.17];
conclusionThe EROS intervention demonstrated marked improvement of reproductive health goal-concordant care, especially among patients who had completed childbearing. The multilevel EROS intervention demonstrates promise to improve adherence to national cancer guidelines at the complex intersection of reproductive health and cancer survivorship.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.